Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock a systematic review and meta-Analysis

JAMA - Journal of the American Medical Association

Volumn 319, Issue 18, 2018, Pages 1889-1900

  McIntyre, William F ^a   Um, Kevin J ^a   Alhazzani, Waleed ^a   Lengyel, Alexandra P ^a   Hajjar, Ludhmila ^b   Gordon, Anthony C ^c,d   Lamontagne, François ^e   Healey, Jeff S ^a   Whitlock, Richard P ^a   Belley Côté, Emilie P ^a  

^a University Hamilton   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; CATECHOLAMINE VASOPRESSOR; HYPERTENSIVE AGENT; UNCLASSIFIED DRUG; VASOPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ACUTE KIDNEY FAILURE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; DIGITAL ISCHEMIA; DISTRIBUTIVE SHOCK; HEART MUSCLE INJURY; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; ISCHEMIA; LENGTH OF STAY; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK REDUCTION; SHOCK; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; FEMALE; MALE; PUBLISHING;

ATRIAL FIBRILLATION; CATECHOLAMINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LENGTH OF STAY; MALE; PUBLICATION BIAS; SHOCK; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 85046723933     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.4528     Document Type: Review

References (50)

1. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345(8): 588-595.
2. Machado FR, Cavalcanti AB, Bozza FA, et al; SPREAD Investigators; Latin American Sepsis Institute Network. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis Prevalence Assessment Database, SPREAD): An observational study. Lancet Infect Dis. 2017;17(11):1180-1189.
3. SepNet Critical Care Trials Group. Incidence of severe sepsis and septic shock in German intensive care units: The prospective, multicentre INSEP study. Intensive Care Med. 2016;42(12):1980-1989.
4. Gkisioti S, Mentzelopoulos SD. Vasogenic shock physiology. Open Access Emerg Med. 2011;3:1-6.
5. Rhodes A, Evans LE, AlhazzaniW, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486-552.
6. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726-1734.
7. DönserMW, Hasibeder WR. Sympathetic overstimulation during critical illness: Adverse effects of adrenergic stress. J Intensive Care Med. 2009;24(5):293-316.
8. Schmittinger CA, Torgersen C, Luckner G, Schröder DC, Lorenz I, DönserMW. Adverse cardiac events during catecholamine vasopressor therapy: A prospective observational study. Intensive Care Med. 2012;38(6):950-958.
9. Levy B, Collin S, Sennoun N, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010;36(12):2019-2029.
10. Klein Klouwenberg PM, Frencken JF, Kuipers S, et al; MARS Consortium. Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis: A cohort study. Am J Respir Crit Care Med. 2017;195(2):205-211.
11. Moss TJ, Calland JF, Enfield KB, et al. New-onset atrial fibrillation in the critically ill. Crit Care Med. 2017;45(5):790-797.
12. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA. 2011;306(20):2248-2254.
13. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95 (5):1122-1125.
14. DönserMW, Mayr AJ, Stallinger A, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med. 2002; 28(6):746-751.
15. De Backer D, Biston P, Devriendt J, et al; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.
16. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. London, United Kingdom: Cochrane Collaboration; 2011.
17. Wan X, WangW, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med ResMethodol. 2014;14(1):135.
18. Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: The VANCS randomized controlled trial. Anesthesiology. 2017;126(1):85-93.
19. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schönemann HJ; GRADEWorking Group. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336(7651):995-998.
20. Abdullah MH, Saleh SM, MoradWS. Terlipressin versus norepinephrine to counteract intraoperative paracentesis induced refractory hypotension in cirrhotic patients. Egyptian Journal of Anaesthesia. 2012;28(1):29-35. doi:10.1016/j.egja .2011.10.002
21. Acevedo JG, Fernandez J, Escorsell A, Mas A, Gines P, Arroyo V. Clinical efficacy and safety of terlipressin administration in cirrhotic patients with septic shock. J Hepatol. 2009;50:S73.
22. Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: A prospective, randomized study. Crit Care Med. 2005;33(9):1897-1902.
23. Barzegar E, Ahmadi A, Mousavi S, Nouri M, Mojtahedzadeh M. The therapeutic role of vasopressin on improving lactate clearance during and after vasogenic shock: microcirculation, is it the black box? Acta Med Iran. 2016;54(1):15-23.
24. Capoletto C, Almeida J, Ferreira G, et al. Vasopressin versus norepinephrine for the management of septic shock in cancer patients (VANCS II). Presented at the Critical Care Conference: 37th International Symposium on Intensive Care and Emergency Medicine; March 21-24, 2017; Brussels, Belgium.
25. Chen Z, Zhou P, Lu Y, Yang C. Comparison of effect of norepinephrine and terlipressin on patients with ARDS combined with septic shock: A prospective single-blind randomized controlled trial [in Chinese]. ZhonghuaWei Zhong Bing Ji Jiu Yi Xue. 2017;29(2):111-116.
26. Choudhury A, Kedarisetty CK, Vashishtha C, et al. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2017;37(4):552-561.
27. Clem O, Painter J, Cullen J, et al. Norepinephrine and vasopressin vs norepinephrine alone for septic shock: randomized controlled trial. Crit Care Med. 2016;44(12):413. doi:10.1097/01.ccm .0000510024.07609.07
28. DönserMW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation. 2003;107(18):2313-2319.
29. Fonseca-Ruiz NJ, Cano ASL, Carmona DPO, et al. Uso de vasopresina en pacientes con choque séptico refractario a catecolaminas: estudio piloto. Acta Colombiana de Cuidado Intensivo. 2013;13(2): 114-123.
30. Gordon AC, Mason AJ, Thirunavukkarasu N, et al; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The vanish randomized clinical trial. JAMA. 2016;316(5):509-518.
31. Han XD, Sun H, Huang XY, et al. A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock [in Chinese]. ZhongguoWei Zhong Bing Ji Jiu Yi Xue. 2012;24(1): 33-37.
32. Hua F, Wang X, Zhu L. Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. J Emerg Med. 2013;44(2):434-439.
33. Lauzier F, Lévy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: A randomized clinical trial. Intensive Care Med. 2006;32(11):1782-1789.
34. Malay MB, Ashton RC, Jr., Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999;47(4):699-703.
35. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): A randomized, controlled pilot study. Crit Care. 2009;13(4):R130.
36. Oliveira S, Dessa F, Rocha C, Oliveira F. Early vasopressin application in shock study. Crit Care. 2014;18:S56. doi:10.1186/cc13348
37. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-Term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96(3):576-582.
38. Prakash V, Choudhury AK, Sarin SK. To assess the efficacy of early introduction of a combination of low dose vasopressin analogue in addition to noradrenaline as a vasopressor in patients of cirrhosis with septic shock. Hepatology. 2017;66 (suppl 1):138A.
39. Russell JA, Walley KR, Singer J, et al; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-887.
40. Russell JA, Vincent JL, Kjølbye AL, et al. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 2017;21(1):213.
41. Svoboda P, Scheer P, Kantorová I, et al. Terlipressin in the treatment of late phase catecholamine-resistant septic shock. Hepatogastroenterology. 2012;59(116):1043-1047.
42. Nagendran M, Maruthappu M, Gordon AC, Gurusamy KS. Comparative safety and efficacy of vasopressors for mortality in septic shock: A network meta-Analysis. J Intensive Care Soc. 2016; 17(2):136-145.
43. Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;2:CD003709.
44. McIntyre WF, Connolly SJ, Healey JS. Atrial fibrillation occurring transiently with stress. Curr Opin Cardiol. 2018;33(1):58-65.
45. Belletti A, Musu M, Silvetti S, et al. Non-Adrenergic vasopressors in patients with or at risk for vasodilatory shock: A systematic review and meta-Analysis of randomized trials. PLoS One. 2015; 10(11):e0142605.
46. Tan J, Chen H, Chen X, Zhang D, He F. Vasopressin and its analog terlipressin versus norepinephrine in the treatment of septic shock: Ameta-Analysis. Int J Clin Exp Med. 2016;9(7): 14183-14190.
47. Russell JA, Fjell C, Hsu JL, et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med. 2013;188(3):356-364.
48. Barrett LK, Orie NN, Taylor V, Stidwill RP, Clapp LH, Singer M. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-Term rodent model of sepsis. Crit Care Med. 2007;35 (10):2337-2343.
49. Smith SM, ValeWW. The role of the hypothalamic-pituitary-Adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006;8(4):383-395.
50. Suzuki Y, Satoh S, Oyama H, Takayasu M, ShibuyaM. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke. 1993;24(7):1049-1053.